SYK Stryker Corporation
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.…
Industry Peers
Medical DevicesKey Statistics
About Stryker (NYSE: SYK)
›
Stryker (NYSE: SYK) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 56,000 employees.
The shares were at 310.00 USD on 20 November 2026, down 13.3% over 52 weeks. Its 52-week range is 267.00 USD to 389.33 USD: the price is 20.4% below the high and 16.1% above the low.
At a market capitalisation of 118.01B USD, it trades at 33.0 times trailing earnings and 19.0 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 24.9, a premium of 33% for SYK. It pays a dividend yielding 1.12% (it pays out 37% of its earnings), against a median of 2.43% among the dividend payers in that peer group.
Stryker reports return on equity of 14.5%, an operating margin of 24.0% and revenue up 7.6% year over year.
Its debt exceeds its cash by 12.16B USD, a debt-to-equity ratio of 0.71. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 27 analysts cover the stock, with an average rating of Buy; their mean price target of 341.48 USD is 10.2% above the current price. The next earnings report is expected on 28 January 2027.